FrancophonIA/ELRC3.0 huggingface dataset:
English: The hard capsule shell is composed of gelatin, titanium dioxide (E171), red iron oxide (E172), yellow iron oxide (E172) and, shellac, black iron oxide (E172), propylene glycol and ammonium hydroxide for stamping of the imprint.
Danish: Den hårde kapsel består af gelatine, titandioxid (E 171), rød jernoxid (E 172), gul jernoxid (E 172) og shellac, sort jernoxid (E 172), propylenglycol og ammoniumhydroxid til prægning.
English: Tasigna 200 mg hard capsules nilotinib
Danish: Tasigna 200 mg hårde kapsler nilotinib
English: Hypericum perforatum); - midazolam - used to relieve anxiety before surgery; - alfentanil and fentanyl - used to treat pain and as a sedative before or during surgery or medical procedures; - cyclosporine, sirolimus and tacrolimus - medicines that suppress the “self-defence” ability of the body and fight infections and are commonly used to prevent the rejection of transplanted organs such as the liver, heart and kidney; - dihydroergotamine and ergotamine - used to treat dementia; - lovastatin, simvastatin - used to treat high level of fats in blood; - warfarin - used to treat blood coagulation disorders (such as blood clots or thromboses); - astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil or ergot alkaloids (ergotamine,
Danish: Det gælder især: - antiarytmika - bruges til at behandle uregelmæssig hjerterytme - chloroquin, halofantrin, clarithromycin, haloperidol, methadon, moxifloxacin - lægemidler, der kan have en uønsket virkning på hjertets elektriske aktivitet - ketoconazol, itraconazol, voriconazol, clarithromycin, telithromycin - bruges til at behandle infektioner - ritonavir - lægemiddel fra klassen ”antiproteaser”, der bruges til at behandle HIV - carbamazepin, phenobarbital, phenytoin - bruges til at behandle epilepsi - rifampicin - bruges til at behandle tuberkulose - perikon - et naturlægemiddel, der bruges til at behandle depression og andre tilstande (kaldes også Hypericum perforatum) - midazolam - bruges til at afhjælpe angst før en operation - alfentanil og fentanyl - bruges til behandling af smerte og som et beroligende middel før eller under operationer eller medicinske indgreb - ciclosporin, sirolimus og tacrolimus - medicin, der undertrykker kroppens ”selvforsvars”-evne og bekæmper infektioner, og er almindeligt anvendt til at forhindre afstødning af transplanterede organer, såsom lever, hjerte og nyre - dihydroergotamin og ergotamin - bruges til behandling af migræne - lovastatin, simvastatin - bruges til at behandle højt niveau af fedt i blodet - warfarin - bruges til at behandle sygdomme, hvor blodet størkner (f.eks. blodpropper eller tromboser) - astemizol, terfenadin, cisaprid, pimozid, quinidin, bepridil.
English: 0 Common
Danish: 0 Almindelig 3
English: Nilotinib 400 mg twice daily n=281
Danish: Nilotinib 400 mg 2 gange dagligt n=281
English: Hypertension, flushing, peripheral artery stenosis
Danish: Hypertension, rødmen, perifer arteriestenose
English: PA/Alu/PVC/Alu [in wallet] 28 hard capsules
Danish: PA/Alu/PVC/Alu [i folder] 28 hårde kapsler
English: If the prior dose was 300 mg twice daily in adult patients or 230 mg/m twice daily in paediatric patients, dosing may be resumed at 400 mg once daily in adult patients and at 230 mg/m once daily in paediatric patients once the toxicity has resolved.
Danish: Hvis den tidligere dosis var 300 mg 2 gange dagligt hos voksne patienter, eller 230 mg/m2 gange dagligt i pædiatriske patienter, kan behandlingen genoptages ved 400 mg 1 gang dagligt hos voksne patienter, og 230 mg/m
English: Adult patients with newly diagnosed chronic phase CML at 300 mg twice daily and imatinib-resistant or intolerant CML in chronic phase at 400 mg twice daily
Danish: Voksne patienter med nydiagnosticeret CML i kronisk fase ved 300 mg 2 gange dagligt og imatinib-resistente eller intolerante patienter med CML i kronisk fase ved 400 mg 2 gange dagligt
English: CARTON OF UNIT PACK (WALLET) CARTON OF UNIT PACK (CARTON)
Danish: ÆSKE MED ENKELTPAKNING (FOLDER) ÆSKE MED ENKELTPAKNING (KARTON)
English: - 392 (14 packs of 28) hard capsules.
Danish: - 392 (14 pakninger med 28) hårde kapsler.
English: Loss of major molecular response (MMR=BCR-ABL/ABL ≤0.1%IS) in CML patients who received nilotinib as first- or second-line therapy, or confirmed loss of MR4 (two consecutive measures separated by at least 4 weeks showing loss of MR4 (MR4=BCR-ABL/ABL ≤0.01%IS)) in CML
Danish: Tab af major molekylært respons (MMR=BCR-ABL/ABL ≤0,1 % IS) hos CML-patienter, som modtog nilotinib som første- eller andenlinje-behandling, eller bekræftet tab af MR4 (to konsekutive målinger med mindst 4 ugers mellemrum, som viser tab af MR4 (MR4=BCR-ABL/ABL ≤0,01% IS)) hos CML-patienter, som modtog nilotinib som andenlinje-behandling, skal medføre genoptagelse af behandlingen senest 4 uger efter tab af remission er blevet konstateret.
English: Most frequently reported adverse reactions in Tasigna clinical studies Non-haematological adverse reactions (excluding laboratory abnormalities) that are reported in at least 5% of the adult patients treated with 300 mg of nilotinib twice daily in the randomised Phase III study are shown in Table 3.
Danish: laboratorieabnormaliteter), som rapporteres hos mindst 5 % af de voksne patienter, som blev behandlet med 300 mg nilotinib 2 gange dagligt i det randomiserede fase III studie, er vist i tabel 3.
English: Papilloedema, chorioretinopathy, diplopia, photophobia, eye swelling, blepharitis, eye pain, conjunctivitis allergic, ocular surface disease Ear and labyrinth disorders Common:
Danish: Papilødem, korioretinopati, diplopi, fotofobi, hævede øjne, blefaritis, smerter i øjnene, allergisk konjunktivitis, okulær overfladesygdom
English: Rare cases of tumour lysis syndrome have been reported in patients treated with Tasigna.
Danish: Sjældne tilfælde af tumorlysesyndrom er blevet rapporteret for patienter behandlet med Tasigna.
English: Tasigna 50 mg hard capsules nilotinib
Danish: Tasigna 50 mg hårde kapsler nilotinib
English: Tasigna 150 mg hard capsules nilotinib
Danish: Tasigna 150 mg hårde kapsler nilotinib
English: The estimated rates of patients alive at 72 months were 91.6%, 95.8% and 91.4%, respectively (HR=0.8934 and stratified log-rank p=0.7085 between nilotinib 300 mg twice daily and imatinib, HR=0.4632 and stratified log-rank p=0.0314 between nilotinib 400 mg twice daily and imatinib).
Danish: De estimerede rater af patienter, der var i live ved 72 måneder, var henholdsvis 91,6 %, 95,8 % og 91,4 % (HR=0,8934 og stratificeret log-rank p=0,7085 mellem nilotinib 300 mg 2 gange dagligt og imatinib, HR=0,4632 og stratificeret log-rank p=0,0314, mellem nilotinib 400 mg 2 gange dagligt og imatinib).
English: The safety and efficacy of Tasigna in paediatric patients with Philadelphia chromosome positive CML in chronic phase from 2 to less than 18 years of age have been established (see sections 4.8, 5.1 and 5.2).
Danish: Sikkerheden og effekten af Tasigna hos pædiatriske patienter, fra 2 til < 18 år, med Philadelphiakromosom-positiv CML i kronisk fase er etableret (se pkt.
English: Therefore, in patients receiving nilotinib, co-administration of alternative therapeutic agents with less potential for CYP3A4 induction should be selected (see section 4.5).
Danish: Derfor bør samtidig administration af alternative lægemidler med mindre potentiale for CYP3A4-induktion vælges til patienter, der samtidig modtager nilotinib (se pkt.
English: Nilotinib 300 mg twice daily (n = 282) Nilotinib 400 mg twice daily (n = 281)
Danish: Nilotinib 300 mg 2 gange dagligt (n = 282) Nilotinib 400 mg 2 gange dagligt (n = 281)
English: QTcF exceeding 500 msec was observed in <1% of patients.
Danish: Der blev observeret QTcF på over 500 msek.
English: The hard capsules are light yellow.
Danish: De hårde kapsler er lysegule.
English: Safety information from a Tasigna treatment discontinuation study in CML patients who have been treated with nilotinib as first-line therapy is also provided.
Danish: Sikkerhedsinformation fra to studier om behandlingsophør med nilotinib er også beskrevet.
English: Febrile neutropenia Immune system disorders Not known:
Danish: Immunsystemet Ikke kendt:
English: Tasigna 50 mg hard capsules
Danish: Tasigna 50 mg hårde kapsler
English: How to take Tasigna
Danish: Sådan skal du tage Tasigna
English: Abdominal distension, abdomnial discomfort, dysgeusia, flatulence
Danish: Abdominal udspiling, abdominalt ubehag, dysgeusi, flatulens
English: Treatment discontinuation in adult Ph+ CML patients in chronic phase who have been treated with nilotinib as first-line therapy and who have achieved a sustained deep molecular response In an open-label, single-arm study, 215 adult patients with Ph+ CML in chronic phase treated with nilotinib in first-line for ≥2 years who achieved MR4.5 as measured with the MolecularMD MRDx BCR-ABL test were enrolled to continue nilotinib treatment for additional 52 weeks (nilotinib consolidation phase).
Danish: Seponering af behandling hos voksne Ph+ CML-patienter i kronisk fase, som har været i behandling med nilotinib som førstelinjebehandling og som har opnået et vedvarende dybt molekylært respons I et enkeltarmet, ikke-blindet studie blev der rekrutteret 215 voksne patienter med Ph+ CML i kronisk fase, som havde fået nilotinib som førstelinjebehandling i ≥2 år og havde opnået MR4.5 målt ved BCR-ABL-testen MolecularMD MRDx Patienterne skulle fortsætte behandling med nilotinib i yderligere 52 uger (nilotinib-konsolideringsfase).
English: Pain in extremity
Danish: Ekstremitets-s merter
English: Some side effects are uncommon (may affect up to 1 in 100 people) - increased skin sensitivity - dry mouth, sore throat, mouth sores - breast pain - painful and swollen joints (gout) - increased appetite - attention disorder - inability to achieve or maintain an erection - breast enlargement in men - flu-like symptoms - pneumonia, bronchitis - urinary tract infection - herpes virus infection - oral or vaginal thrush - muscle and joint stiffness, joint swelling - feeling body temperature change (including feeling hot, feeling cold) - sensitive teeth
Danish: Nogle bivirkninger er ikke almindelige (kan påvirke op til 1 ud af 100 patienter) - øget hudfølsomhed - tør i munden, ondt i halsen, sår i munden - smerter i brystet - smerter og hævede led (gigt) - øget appetit - opmærksomhedsforstyrrelse - kan ikke opnå eller opretholde rejsning - brystforstørrelse hos mænd - influenzalignende symptomer - lungebetændelse, bronkitis - urinvejsinfektion - herpes virus infektion - svamp i munden eller skeden - stivhed i muskler og led, hævede led - følelse af, at kropstemperaturen ændrer sig (inklusive svedeture, kuldefølelse) - følsomme tænder
English: Based on a reduction in body weight in both genders and a delayed preputial separation in males (which may be associated with the reduction in weight), the No-Observed-Effect-Level in juvenile rats was considered to be 6 mg/kg/day.
Danish: No Observed Effect Level (NOEL) for unge rotter anses for at være 6 mg/kg/dag baseret på en reduktion i kropsvægt hos begge køn og en forsinket preputial seperation hos hanrotter (som kan skyldes vægtreduktionen).
English: - 120 (3 packs of 40) hard capsules.
Danish: - 120 (3 pakninger med 40) hårde kapsler.
English: The recommended dose of nilotinib is 230 mg/m twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg) (see Table 1).
Danish: Dosering til pædiatriske Philadelphiakromosom-positive CML-patienter Dosering til pædiatriske patienter er individuelt tilpasset og er baseret på kropsoverfladeareal (mg/m Den anbefalede dosis af nilotinib er 230 mg/m2 gange dagligt, afrundet til nærmeste 50 mg dosis (til en maksimal enkeltdosis på 400 mg) (se tabel 1).
English: The estimated rates of patients free from progression to accelerated phase or blast crisis including clonal evolution at 72 months were 98.7%, 97.9% and 93.2%, respectively (HR=0.1626 and stratified log-rank p=0.0009 between nilotinib 300 mg twice daily and imatinib once daily, HR=0.2848 and stratified log-rank p=0.0085 between nilotinib 400 mg twice daily and imatinib once daily).
Danish: De estimerede rater af patienter uden progression til accelereret fase eller blastkrise inklusive klonal evolution ved 72 måneder var henholdsvis 98,7 %, 97,9 % og 93,2 % (HR=0,1626 og stratificeret log-rank p=0,0009 mellem nilotinib 300 mg 2 gange dagligt og imatinib 1 gang dagligt, HR=0,2848 og stratificeret log-rank p=0,0085 mellem nilotinib 400 mg 2 gange dagligt og imatinib 1 gang dagligt).
English: A total of 199 (35.2%) of all patients were not evaluable for MMR at 36 months (87 in the nilotinib 300 mg twice daily group and 112 in the imatinib group) due to missing/unevaluable PCR assessments (n=17), atypical transcripts at baseline (n=7), or discontinuation prior to the 36-month time point (n=175).
Danish: I alt 199 (35,2 %) af alle patienter var ikke evaluerbare for MMR ved 36 måneder (87 i nilotinib-gruppen, der fik 300 mg 2 gange dagligt og 112 i imatinib-gruppen) på grund af manglende/ikke evaluerbare PCR-vurderinger (n=17), atypiske transkriptioner ved baseline (n=7), eller ophør før 36-måneder (n=175).
English: During Tasigna treatment, you may also have some abnormal blood test results such as: low level of blood cells (white cells, red cells, platelets) or haemoglobin increase in the number of platelets or white cells, or specific types of white cells (eosinophils) in the blood high blood level of lipase or amylase (pancreas function) high blood level of bilirubin or liver enzymes (liver function) high blood level of creatinine or urea (kidney function) low or high blood level of insulin (a hormone regulating blood sugar level) low or high level of sugar, or high level of fats (including cholesterol) in the blood high blood level of parathyroid hormone (a hormone regulating calcium and phosphorus level) change in blood proteins (low level of globulins or presence of paraprotein) high blood levels of enzymes (alkaline phosphatase, lactate dehydrogenase or creatine phosphokinase) high blood level of potassium, calcium, phosphorus or uric acid low blood level of magnesium, potassium, sodium, calcium, or phosphorus
Danish: (eosinofiler) i blodet - øget indhold i blodet af lipase eller amylase (funktionen af bugspytkirtlen) - øget indhold i blodet af bilirubin eller leverenzymer (leverfunktionen) - øget indhold af kreatinin eller urinstof (nyrefunktionen) i blodet - lavt eller højt indhold af insulin i blodet (hormon, der regulerer blodsukkeret) - lavt eller højt indhold af sukker eller højt fedt-indhold (herunder kolesterol) i blodet - øget indhold af parathyroideahormon (et hormon som regulerer indholdet af calcium og fosfor) i blodet - ændringer af proteiner (lavt antal af globuliner eller tilstedeværelse af paraprotein) i blodet - højt indhold af enzymer (alkalisk fosfatase, laktatdehydrogenase eller kreatininfosfokinase) i blodet - højt indhold af kalium, calcium, fosfor eller urinsyre i blodet - lavt indhold af magnesium, kalium, natrium, calcium eller fosfor i blodet
English: Considering only CML-related deaths as events, the estimated rates of overall survival at 72 months were 97.7%, 98.5% and 93.9%, respectively (HR=0.3694 and stratified log-rank p=0.0302 between nilotinib 300 mg twice daily and imatinib, HR=0.2433 and stratified log-rank p=0.0061 between nilotinib 400 mg twice daily and imatinib).
Danish: Hvis kun CML-relaterede dødsfald tages i betragtning, var de estimerede rater for total overlevelse ved 72 måneder henholdsvis 97,7 %, 98,5 % og 93,9 % (HR=0,3694 og stratificeret log-rank p=0,0302 mellem nilotinib 300 mg 2 gange dagligt og imatinib, HR=0,2433 og stratificeret log-rank p=0,0061,mellem nilotinib 400 mg 2 gange dagligt og imatinib).
English: During Tasigna treatment, you may also have some abnormal blood test results such as: - low level of blood cells (white cells, red cells, platelets) or haemoglobin - increase in the number of platelets or white cells, or specific types of white cells (eosinophils) in the blood - high blood level of lipase or amylase (pancreas function) - high blood level of bilirubin or liver enzymes (liver function) - low or high blood level of insulin (a hormone regulating blood sugar level) - low or high level of sugar, or high level of fats (including cholesterol) in the blood - high blood level of parathyroid hormone (a hormone regulating calcium and phosphorus level) - change in blood proteins (low level of globulins or presence of paraprotein) - high blood level of alkaline phosphatase - high blood level of potassium, calcium, phosphorus or uric acid - low blood level of potassium or calcium
Danish: (eosinofiler) i blodet - øget indhold i blodet af lipase eller amylase (funktionen af bugspytkirtlen) - øget indhold i blodet af bilirubin eller leverenzymer (leverfunktionen) - lavt eller højt indhold af insulin i blodet (hormon, der regulerer blodsukkeret) - lavt eller højt indhold af sukker eller højt fedt-indhold (herunder kolesterol) i blodet - øget indhold af parathyroideahormon (et hormon som regulerer indholdet af calcium og fosfor) i blodet - ændringer af proteiner (lavt antal af globuliner eller tilstedeværelse af paraprotein) i blodet - højt indhold af alkalisk fosfatase i blodet - højt indhold af kalium, calcium, fosfor eller unrinsyre i blodet - lavt indhold af kalium eller calcium i blodet
English: 120 (3 packs of 40) hard capsules.
Danish: 120 (3 pakninger med 40) hårde kapsler.
English: Titanium dioxide (E171) Yellow iron oxide (E172)
Danish: Titandioxid (E 171) Jernoxid, gul (E 172)
English: Some side effects are common (may affect up to 1 in 10 people) - diarrhoea, vomiting, abdominal pain, stomach discomfort after meals, flatulence, swelling or bloating of the abdomen, constipation - bone pain, pain in joints, muscle spasms, muscle weakness, pain in extremity, back pain, pain or discomfort in the side of the body - upper respiratory tract infections - dry skin, acne, wart, decreased skin sensitivity - loss of appetite, disturbed sense of taste, weight increase - insomnia, anxiety, depression - night sweats, excessive sweating
Danish: Nogle bivirkninger er almindelige (kan påvirke op til 1 ud af 10 patienter) - diarré, opkastning, mavesmerter, ubehag i maven efter måltider, luft i tarmene, hævelse eller opsvulmen af maven, forstoppelse - smerter i knoglerne, smerter i leddene, muskelspasmer, muskelsvaghed, smerter i armene eller benene, rygsmerter, smerte eller ubehag i siden af kroppen - infektioner i de øvre lufveje - tør hud, urenheder i huden, vorter, mindsket hudfølsomhed - tab af appetit, smagsforstyrrelser, vægtstigning - søvnløshed, angst, depression - natlige svedeture, stor svedafsondring
English: Some side effects are very common (may affect more than 1 in 10 people) - headache - tiredness - muscle pain - itching, rash - nausea - hair loss - musculoskeletal pain, muscle pain, pain in extremity, pain in joints, bone pain and spinal pain upon discontinuing treatment with Tasigna - slowing of growth in children and adolescents
Danish: Nogle bivirkninger er meget almindelige (kan påvirke mere end 1 ud af 10 patienter) - hovedpine - træthed - muskelsmerte - kløe, udslæt - kvalme - hårtab - muskelskeletale smerter, muskelsmerter, smerter i arme og/eller ben, ledsmerter, knoglesmerter og ryg smerter efter ophør med behandlingen med Tasigna langsommere vækst hos børn og unge
English: 9/l and/or platelet counts <10 x 10
Danish: 9/l og/eller trombocytter <10 x 10
English: Some side effects are common (may affect up to 1 in 10 people) - upper respiratory tract infections - stomach discomfort after meals, flatulence, swelling or bloating of the abdomen - bone pain, pain in joints, muscle spasms, muscle weakness - pain including back pain, neck pain and pain in extremity, pain or discomfort in the side of the body - dry skin, acne, wart, decreased skin sensitivity, hives - loss of appetite, disturbed sense of taste, weight decrease or increase - insomnia, depression, anxiety - night sweats, excessive sweating - generally feeling unwell - voice disorder - nose bleed - frequent urine output
Danish: Nogle bivirkninger er almindelige (kan påvirke op til 1 ud af 10 patienter) - infektioner i de øvre lufveje - ubehag i maven efter måltider, luft i tarmene, hævelse eller opsvulmen af maven - smerter i knoglerne, smerter i leddene, muskelspasmer, muskelsvaghed - smerter inklusive rygsmerter, nakkesmerter og smerter i lemmerne, smerte eller ubehag i siden af kroppen - tør hud, urenheder i huden, vorte, mindsket hudfølsomhed, nældefeber - tab af appetit, smagsforstyrrelser, vægtstigning eller vægttab - søvnløshed, depression, angst - natlige svedeture, stor svedafsondring - generel utilpashed - forstyrrelser af stemmen - næseblod - hyppig vandladning
English: The estimated rates of patients free from progression to accelerated phase or blast crisis at 72 months were 99.3%, 98.7% and 95.2%, respectively (HR=0.1599 and stratified log-rank p=0.0059 between nilotinib 300 mg twice daily and imatinib once daily, HR=0.2457 and stratified log-rank p=0.0185 between nilotinib 400 mg twice daily and imatinib once daily).
Danish: De estimerede rater af patienter uden progression til accelereret fase eller blastkrise ved 72 måneder, var henholdsvis 99,3 %, 98,7 % og 95,2 % (HR=0,1599 og stratificeret log-rank p=0,0059 mellem nilotinib 300 mg 2 gange dagligt og imatinib 1 gang dagligt, HR=0,2457 og stratificeret log-rank p=0,0185 mellem nilotinib 400 mg 2 gange dagligt og imatinib 1 gang dagligt).
English: Some side effects are very common (may affect more than 1 in 10 people) - diarrhoea - headache - tiredness, lack of energy - muscle pain - itching, rash - nausea - abdominal pain - constipation - vomiting - hair loss - musculoskeletal pain, muscle pain, pain in extremity, pain in joints, bone pain and spinal pain upon discontinuing treatment with Tasigna - slowing of growth in children and adolescents
Danish: Nogle bivirkninger er meget almindelige (kan påvirke mere end 1 ud af 10 patienter) - diarré - hovedpine - træthed, mangel på energi - muskelsmerte - kløe, udslæt - kvalme - mavesmerter - forstoppelse - opkastning - hårtab - muskelskeletale smerter, muskelsmerter, smerter i arme og/eller ben, ledsmerter, knoglesmerter og rygsmerter efter ophør med behandlingen med Tasigna - langsommere vækst hos børn og unge
English: Posology for Philadelphia chromosome positive CML adult patients The recommended dose is: - 300 mg twice daily in newly diagnosed patients with CML in the chronic phase, - 400 mg twice daily in patients with chronic or accelerated phase CML with resistance or intolerance to prior therapy.
Danish: Dosering til voksne Philadelphiakromosom-positive CML-patienter Den anbefalede dosis er: - 300 mg 2 gange dagligt til patienter med nydiagnosticeret CML i kronisk fase.
English: Imatinib 400 mg once daily n=283
Danish: Imatinib 400 mg 1 gang dagligt n=283
English: In the Phase III study in patients with newly diagnosed CML in chronic phase receiving 300 mg nilotinib twice daily, the change from baseline in mean time-averaged QTcF interval at steady state was 6 msec. No patient had a QTcF >480 msec. No episodes of torsade de pointes were observed.
Danish: I fase III-studiet med patienter med nydiagnosticeret CML i kronisk fase, som behandledes med 300 mg imatinib to gange dagligt, var den gennemsnitlige ændring fra baseline i QTcF-intervallet ved steady state 6 msek.
English: White to yellowish powder in hard gelatin capsule with red opaque cap and light yellow opaque body, size 4 with black radial imprint “NVR/ABL” on cap.
Danish: Hvidt til gulligt pulver i hård gelatinekapsel med rød, uigennemsigtig øverste del og lysegul, uigennemsigtig nederste del, størrelse 4 med ”NVR/ABL” præget med sort på øverste del. Tasigna 200 mg hårde kapsler
English: Eyelid oedema, photopsia, conjunctival haemorrhage, hyperaemia (scleral, conjunctival, ocular)
Danish: Øjenlågsødem, fotopsi, konjunktival blødning, hyperæmi (skleral, konjunktival, okulær)